培塞利珠单抗治疗活动性非放射学中轴型脊柱关节炎的长期安全性与临床结局:3期C-axSpAnd研究3年结果
C-axSpAnd研究纳入317例活动性非放射学中轴型脊柱关节炎且伴客观炎症征象的患者,随机接受安慰剂或培塞利珠单抗200 mg每2周1次治疗1年,随后开放标签延伸治疗2年。243例进入延伸期,截至第156周,临床结局在第1年取得的改善得以维持,MRI骶髂关节炎症评分持续处于低水平,安全性与既往报告一致。
要点
- 243/317(76.7%)患者进入开放标签延伸期,其中149例(61.3%)发生至少1次治疗中出现的不良事件。
- 初始培塞利珠单抗组ASDAS在第52周为1.8,第156周维持1.8;BASDAI第52周2.7,第156周2.6。
- 初始培塞利珠单抗组SPARCC MRI骶髂关节炎症评分基线7.6,第52周降至1.7,第156周维持低水平2.4。
核心结论
- 培塞利珠单抗治疗活动性非放射学中轴型脊柱关节炎至3年耐受性良好,与既往报告相比无新的安全性信号。
- 治疗1年后达到的临床结局维持至3年。
研究设计与样本
- C-axSpAnd为3期研究,包括1年双盲安慰剂对照期和2年开放标签安全性随访延伸期。
- 基线时317例患者按1:1随机分配至安慰剂或培塞利珠单抗200 mg每2周1次。
- 完成双盲期并进入延伸期的患者接受开放标签培塞利珠单抗额外104周治疗。
- 长期安全性与临床结局报告至第156周,连续变量以观察病例呈现,二分类变量以观察病例和無应答者填补呈现。
主要发现
- 243/317(76.7%)患者进入延伸期,其中149例(61.3%)发生至少1次治疗中出现的不良事件。
- 15例发生严重治疗中出现的不良事件,发生率为3.3/100患者年。
- 初始培塞利珠单抗随机组第52周ASDAS为1.8、BASDAI为2.7,第156周分别为1.8和2.6。
- 初始培塞利珠单抗随机组SPARCC MRI骶髂关节炎症评分基线7.6,第52周1.7,第156周2.4。
关键数值与推荐
- 初始培塞利珠单抗随机组第52周ASDAS 1.8,第156周1.8。
- 初始培塞利珠单抗随机组第52周BASDAI 2.7,第156周2.6。
- 初始培塞利珠单抗随机组SPARCC MRI骶髂关节炎症评分基线7.6,第52周1.7,第156周2.4。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 52-week results from C-axSpAnd demonstrated the safety and efficacy of certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (sacroiliitis on MRI and/or elevated C-reactive protein levels). Long-term safety and clinical outcomes, including MRI assessments, are evaluated up to 3 years for CZP-treated patients with nr-axSpA. METHODS: C-axSpAnd was a phase 3 study comprising a 1-year double-blind, placebo-controlled period and 2-year open-label safety follow-up extension (SFE). At baseline, 317 patients were randomised 1:1 to placebo or CZP 200 mg every 2 weeks. Patients completing the double-blind phase who enrolled into the SFE received open-label CZP for an additional 104 weeks. Long-term safety and clinical outcomes are reported to Week 156. Continuous outcomes are presented as observed case (OC) and dichotomous outcomes as OC and with non-responder imputation. RESULTS: 243/317 (76.7%) patients entered the SFE, during which 149 (61.3%) experienced ≥1 treatment-emergent adverse event (TEAE); 15 (3.3/100 patient-years) experienced serious TEAEs. Continuous outcome scores (including Ankylosing Spondylitis Disease Activity Score [ASDAS]: 1.8; Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]: 2.7) at Week 52 were maintained at Week 156 (ASDAS: 1.8; BASDAI: 2.6) for the initial CZP-randomised group. Mean SPARCC MRI sacroiliac joint inflammation scores for these patients decreased at Week 52 (baseline: 7.6; Week 52: 1.7), remaining low at Week 156 (2.4). CONCLUSIONS: CZP treatment was well tolerated up to 3 years, with no new safety signals versus previous reports. Clinical outcomes achieved after 1 year were sustained to 3 years. TRIAL REGISTRATION NUMBER: NCT02552212.
引用
- van der Heijde D, Gensler LS, Maksymowych WP, et al. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open. 2022. PMID: 35296532. doi:10.1136/rmdopen-2021-002138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。